Nagatani T, Kin S, Baba N, Miyamoto H, Nakajima H
Nihon Hifuka Gakkai Zasshi. 1989 Apr;99(5):579-91.
We investigated the pretreatment characteristics and prognosis of T-cell lymphomas, including mycosis fungoides (MF), T-cell lymphoma of the skin other than MF (CTL), adult T-cell leukemia/lymphoma (ATL), immunoblastic lymphadenopathy (IBL)-like T-cell lymphoma and angioimmunoblastic lymphadenopathy with dysproteinemia (AILD), as well as B-cell lymphoma of the skin (CBL) and analyzed the prognostic factors for skin T-cell lymphoma when the skin was the organ initially or predoienantly involved. Twenty-eight cases of erythematous-stage MF, ten cases of plaque-stage MF, eleven cases of tumor-stage MF, twelve cases of ATL, eleven cases of IBL-like T-cell lymphoma/AILD, and eight cases of CBL were studied. CTCL patients were treated by photochemotherapy with topical 8-methoxypsoralen (8-MOP) followed by VUA irradiation, electron-beam irradiation, or systemic chemotherapy. Complete remission (CR) was obtained with all of these therapies. However induction of CR was not a major prognostic factor in skin T-cell lymphoma, and the clinical stage was more valuable in this respect. No cases of death occurred among erythematous-stage MF patients, but eight out of 11 patients with tumor-stage MF died (mean survival rate, 38 months). The prognosis for tumor-stage MF was better than that of ATL (19 months) or IBL-like T cell lymphoma/AILD (28 months), but worse than those of erythematous-a plaque-stage MF. TNM staging of CTCL was also a useful factor for prognosis.
我们研究了T细胞淋巴瘤的预处理特征和预后，包括蕈样肉芽肿（MF）、MF以外的皮肤T细胞淋巴瘤（CTL）、成人T细胞白血病/淋巴瘤（ATL）、免疫母细胞性淋巴结病（IBL）样T细胞淋巴瘤和伴有蛋白异常血症的血管免疫母细胞性淋巴结病（AILD），以及皮肤B细胞淋巴瘤（CBL），并分析了皮肤最初或主要受累时皮肤T细胞淋巴瘤的预后因素。研究了28例红斑期MF、10例斑块期MF、11例肿瘤期MF、12例ATL、11例IBL样T细胞淋巴瘤/AILD和8例CBL。CTCL患者接受光化学疗法治疗，外用8-甲氧基补骨脂素（8-MOP），随后进行紫外线A照射、电子束照射或全身化疗。所有这些疗法均获得完全缓解（CR）。然而，CR的诱导不是皮肤T细胞淋巴瘤的主要预后因素，在这方面临床分期更有价值。红斑期MF患者无死亡病例，但11例肿瘤期MF患者中有8例死亡（平均生存率38个月）。肿瘤期MF的预后优于ATL（19个月）或IBL样T细胞淋巴瘤/AILD（28个月），但比红斑期-斑块期MF差。CTCL的TNM分期也是一个有用的预后因素。
